Drugs / Boryung Cell Culture Japanese Encephalitis Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02532569 | Aug 2015 → Oct 2016 | Japanese encephalitis | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Boryung Cell Culture Japanese Encephalitis Vaccine | “All subjects were subcutaneously vaccinated once for the booster immunization with Boryung Cell Culture Japanese Encephalitis Vaccine® (JE-VC).” PMID 29429815 ↗ Mar 2018 |
| Known as | JE-VC | “All subjects were subcutaneously vaccinated once for the booster immunization with Boryung Cell Culture Japanese Encephalitis Vaccine® (JE-VC).” PMID 29429815 ↗ Mar 2018 |
| Modality | Vaccine | “an inactivated, Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC)” PMID 29429815 ↗ Mar 2018 |
| Route | Subcutaneous | “0.5-mL dose is administered subcutaneously in the lateral aspect of the upper arm.” NCT02532569 ↗ |